NFE2L2 and lung cancer: Additionally, we evaluated the effectiveness of the RSL3 on lung cancer cell lines (Figures 5B and 5C) and observe that H2009 cells, which have a high NRF2-signature and high basal LD levels are more resistant to RSL3 than H1650 cells, which have a low NRF2-signature and low basal LD levels.